Session Information
Date: Tuesday, June 6, 2017
Session Title: Rare Genetic and Metabolic Diseases
Session Time: 1:45pm-3:15pm
Location: Exhibit Hall C
Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and others
Background: Rare diseases (RD) collectively are very common and encompass more than 7000 different disorders, but the number continues to grow every year. Movement disorders constitute the hallmark feature of several RD and a significant proportion of these disorders are amenable to treatment. Although effective symptomatic treatment are available for many rare movement disorders (RMD), some are amenable to pathogenesis-targeted therapeutic strategies
Methods: Our study group performed a systematic literature review to identify treatable RMD for which evidence for effective treatment exists.
Results: We identified at least 33 treatable RMD affecting children and adults. Different targets for these treatable conditions include dietary intervention in 9/33 (i.e.abetalipoproteinemia); avoidance of triggers 8/33 (e.g. glutaric aciduria type 1), enzyme replacement or substrate reduction 2/33 (e.g. Gaucher disease, Niemann-Pick type C), vitamin supplementation 6/33 (e.g. biotinidase deficiency), dopamine replacement 6/33 (e.g. dopa-responsive disorders), copper depleting agents 2/33 (e.g., Wilson disease), replacement therapies 2/33 (e.g., chenodeoxycholic acid in cerebrotendinous xanthomatosis), compensatory enzymatic activity 1/33 (e.g. Aromatic amino acid decarboxylase deficiency ) and ion channel modulation 2/33( e.g. Episodic ataxia type 2)
Conclusions: Increased awareness of treatable RMD through a systematic approach may facilitate the use of specific treatments capable of preventing, improving, or reversing neurological damage associated with this group of movement disorders.
To cite this abstract in AMA style:
E. Gatto, H. Jinnah, A. Espay, J. Jankovic, K. Bhatia, M. Rodriguez, V. Fung, F. Cardoso, M. Rodriguez Oroz, A. Albanese, A. Muenchau, A. Chade, M. de Koning-Tijssen, M. Stamelou, P. Garcia Ruiz, C. Uribe Roca, F. Morgante, A. Dela Cerda, L. Schoels, J. Miyasaki, J. Ferreira. Treatable Rare Movement Disorders [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/treatable-rare-movement-disorders/. Accessed November 22, 2024.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/treatable-rare-movement-disorders/